Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World Practice
Glezer M. G., Vygodin V. A., Nekrasova E. L., Khlopina I. A., Nubret K. S., Agafonova Y. A., Ternavsky S. P., Bardukova O. V., Kutyakova N. M., Berestennikova Y. V., Ustyugova V. V., Filatova T. A., Khalturina I. G., Ishchenko K. A., Karutskaja O. A., Panikar V. I., Bolkhovitina O. A., Bondarev E. I., Eremin I. N., Kadashova S. I., Frolova O. M., Petukhova I. L., Suvorov A. V., Zhuchkova Y. V., Kuhl M. A., Rodionova L. V., Musurok T. P., Ivkova I. A., Ermakov A. S., Stukalova E. M., Chumakov V. N., Rubezhanskaja E. Y., Kotlova A. A., Pushkareva A. V., Dmitrieva L. V., Bel’kina E. V., Solov’eva O. E., Panyulaytenene S. L., Sarkisyan O. G., Konovalova G. V., Kuznetsova S. S., Nikolaeva S. V., Trubitsyna I. V., Alekseeva O. A., Kozmina M. E., Babautseva N. A., Kochetkova I. V., Anokhin A. A., Vovk E. V., Buyko A. N., Malahatka E. S., Iskra M. A., Shilonosov S. N., Moiseenko G. V., Tomm Y. S., Stopyatuk N. A., Grigorieva E. G., Zaitseva A. A., Zaitseva N. A., Sirotkina I. A., Kiyanichenko R. L., Grigoriev S. P., Medvedeva N. V., Svatkov M. Y., Golubeva L. V., Kozhevnikova L. A.
Advances in Therapy
Vol.35, Issue9, P. 1368-1377
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1007/s12325-018-0756-3
Аннотация:
Introduction: Trimetazidine (TMZ) was shown to reduce angina symptoms and increase the exercise capacity in stable angina (SA) patients. A new formulation allowing a once-daily (od) dosage could improve patients’ satisfaction and adherence. Methods: ODA was a 3-month, observational, multicenter, prospective Russian study in SA patients with persistent symptoms despite therapy. Angina attack frequency, short-acting nitrate (SAN) consumption, adherence to antianginal medications, and overall efficacy and tolerability of TMZ 80 mg od were assessed in a real-world setting. Results: A total of 3066 patients were included (mean age 62.8, 48[%] male). After 3 months, TMZ 80 mg od treatment led to a significant (p < 0.001) decrease in angina attack frequency (from 4.7 ± 3.5 to 0.9 ± 1.3/week) and SAN use (from 4.5 ± 3.9 to 0.7 ± 1.3/week). Overall tolerability and effectiveness were rated as “very good” by the majority of physicians. Medication adherence improved significantly, with good adheren
Ключевые слова:
Cardiology; Observational study; Real-world evidence; Stable angina; Trimetazidine
angiotensin receptor antagonist; beta adrenergic receptor blocking agent; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; hydroxymethylglutaryl coenzyme A reductase inhibitor; ivabradine; molsidomine; nicorandil; nitric acid derivative; ranolazine; trimetazidine; trimetazidine; vasodilator agent; adult; aged; Article; dizziness; drug efficacy; drug tolerability; female; functional status; headache; hospitalization; human; major clinical study; male; medication compliance; multicenter study; nausea; observational study; patient compliance; patient satisfaction; physical activity; prospective study; stable angina pectoris; treatment duration; clinical trial; delayed release formulation; middle aged; Russian Federation; stable angina pectoris; Aged; Angina, Stable; Delayed-Action Preparations; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Prospective Studies; Russia; Trimetazidine; Vasodilator Agents
Язык текста: Английский
ISSN: 1865-8652
Glezer M. G. Mariya Genrikhovna 1952-
Vygodin V. A.
Nekrasova E. L.
Khlopina I. A.
Nubret K. S.
Agafonova Y. A.
Ternavsky S. P.
Bardukova O. V.
Kutyakova N. M.
Berestennikova Y. V.
Ustyugova V. V.
Filatova T. A.
Khalturina I. G.
Ishchenko K. A.
Karutskaja O. A.
Panikar V. I.
Bolkhovitina O. A.
Bondarev E. I.
Eremin I. N.
Kadashova S. I.
Frolova O. M.
Petukhova I. L.
Suvorov A. V.
Zhuchkova Y. V.
Kuhl M. A.
Rodionova L. V.
Musurok T. P.
Ivkova I. A.
Ermakov A. S.
Stukalova E. M.
Chumakov V. N.
Rubezhanskaja E. Y.
Kotlova A. A.
Pushkareva A. V.
Dmitrieva L. V.
Bel’kina E. V.
Solov’eva O. E.
Panyulaytenene S. L.
Sarkisyan O. G.
Konovalova G. V.
Kuznetsova S. S.
Nikolaeva S. V.
Trubitsyna I. V.
Alekseeva O. A.
Kozmina M. E.
Babautseva N. A.
Kochetkova I. V.
Anokhin A. A.
Vovk E. V.
Buyko A. N.
Malahatka E. S.
Iskra M. A.
Shilonosov S. N.
Moiseenko G. V.
Tomm Y. S.
Stopyatuk N. A.
Grigorieva E. G.
Zaitseva A. A.
Zaitseva N. A.
Sirotkina I. A.
Kiyanichenko R. L.
Grigoriev S. P.
Medvedeva N. V.
Svatkov M. Y.
Golubeva L. V.
Kozhevnikova L. A.
Глезер М. Г. Мария Генриховна 1952-
Вyгодин В. А.
Некрасова Е. Л.
Хлопина И. А.
Нубрет К. С.
Агафонова Y. А.
Тернавскy С. П.
Бардукова О. В.
Кутякова Н. М.
Берестенникова Y. В.
Устюгова В. В.
Филатова Т. А.
Халтюрина И. Г.
Ишченко К. А.
Каруцкайа О. А.
Паникар В. И.
Болховитина О. А.
Бондарев Е. И.
Еремин И. Н.
Кадашова С. И.
Фролова О. М.
Петюхова И. Л.
Суворов А. В.
Жучкова Y. В.
Кухл М. А.
Родионова Л. В.
Мусурок Т. П.
Ивкова И. А.
Ермаков А. С.
Стюкалова Е. М.
Чумаков В. Н.
Рубежанскайа Е. Y.
Котлова А. А.
Пушкарева А. В.
Дмитриева Л. В.
Бел’кина Е. В.
Солов’ева О. Е.
Панюлайтенене С. Л.
Саркисян О. Г.
Коновалова Г. В.
Кузнецова С. С.
Николаева С. В.
Трубицyна И. В.
Алексеева О. А.
Козмина М. Е.
Бабауцева Н. А.
Кочеткова И. В.
Анохин А. А.
Вовк Е. В.
Буyко А. Н.
Малахатка Е. С.
Искра М. А.
Шилоносов С. Н.
Моисеенко Г. В.
Томм Y. С.
Стопятюк Н. А.
Григориева Е. Г.
Заицева А. А.
Заицева Н. А.
Сироткина И. А.
Кияниченко Р. Л.
Григориев С. П.
Медведева Н. В.
Сватков М. Y.
Голубева Л. В.
Кожевникова Л. А.
Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World Practice
Текст визуальный непосредственный
Advances in Therapy
Health Communications, Inc.
Vol.35, Issue9 P. 1368-1377
2018
Статья
Cardiology Observational study Real-world evidence Stable angina Trimetazidine
angiotensin receptor antagonist beta adrenergic receptor blocking agent calcium channel blocking agent dipeptidyl carboxypeptidase inhibitor hydroxymethylglutaryl coenzyme A reductase inhibitor ivabradine molsidomine nicorandil nitric acid derivative ranolazine trimetazidine trimetazidine vasodilator agent adult aged Article dizziness drug efficacy drug tolerability female functional status headache hospitalization human major clinical study male medication compliance multicenter study nausea observational study patient compliance patient satisfaction physical activity prospective study stable angina pectoris treatment duration clinical trial delayed release formulation middle aged Russian Federation stable angina pectoris Aged Angina, Stable Delayed-Action Preparations Female Humans Male Medication Adherence Middle Aged Patient Satisfaction Prospective Studies Russia Trimetazidine Vasodilator Agents
Introduction: Trimetazidine (TMZ) was shown to reduce angina symptoms and increase the exercise capacity in stable angina (SA) patients. A new formulation allowing a once-daily (od) dosage could improve patients’ satisfaction and adherence. Methods: ODA was a 3-month, observational, multicenter, prospective Russian study in SA patients with persistent symptoms despite therapy. Angina attack frequency, short-acting nitrate (SAN) consumption, adherence to antianginal medications, and overall efficacy and tolerability of TMZ 80 mg od were assessed in a real-world setting. Results: A total of 3066 patients were included (mean age 62.8, 48[%] male). After 3 months, TMZ 80 mg od treatment led to a significant (p < 0.001) decrease in angina attack frequency (from 4.7 ± 3.5 to 0.9 ± 1.3/week) and SAN use (from 4.5 ± 3.9 to 0.7 ± 1.3/week). Overall tolerability and effectiveness were rated as “very good” by the majority of physicians. Medication adherence improved significantly, with good adheren